Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 6, 1996, Pages 1319-1323

  Frantz, Christopher E ^a   Chen, Hongwei ^a,b   Eastmond, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Benzene; Chromosome aberrations; Leukemia; Topoisomerase II

Indexed keywords

1,2,4 BENZENETRIOL; 1,4 BENZOQUINONE; 2,2' BIPHENYLDIOL; 4,4' DIHYDROXYBIPHENYL; BENZENE; CARCINOGEN; CATECHOL; DNA TOPOISOMERASE (ATP HYDROLYSING); HYDROQUINONE; MUCONALDEHYDE; PEROXIDASE; PHENOL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME INHIBITION; GENOTOXICITY; LEUKEMIA; METABOLITE; PRIORITY JOURNAL;

EID: 0030446664     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.961041319     Document Type: Conference Paper

References (48)

1. IARC, Evaluation of the Carcinogenic Risk of Chemicals to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1-42. IARC Monograph Supplement 7. Lyon:International Agency for Research on Cancer, 1987:120-122.
2. Aksoy M. Benzene Carcinogenicity. In: Beniene Carcinogenicity (Aksoy M, ed). Boca Raton, FL:CRC Press, 1988;113-151.
3. Eastmond, DA. Induction of micronuclei and aneuploidy by the quinone-forming agents benzene and ο-phenylphenol. Toxicol Lett 67:105-118 (1993).
4. Chen H, Rupa DS, Tomar R, Eastmond DA. Chromosomal loss and breakage in mouse bone marrow and spleen cells exposed to benzene in vivo. Cancer Res 54:3533-3539 (1994).
5. Chen H, Eastmond DA. Synergistic increase in chromosomal breakage within the euchromatin induced by an interaction of the benzene metabolites phenol and hydroquinone in mice. Carcinogenesis 16:1963-1969 (1995).
6. Dean BJ. Recent findings on the genetic toxicology of benzene, toluene, xylenes and phenols. Mutat Res 154:153-181 (1985).
7. Waters MD, Stack HF, Brady AL, Lohman PHM, Haroun L, Vainio H. Use of computerized data listings and activity profiles of genetic and related effects in the reviews of 195 compounds. Mutat Res 205:295-312 (1988).
8. Lutz WK. Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J Cancer Res Clin Oncol 112:85-91 (1986).
9. Reddy MV, Blackburn GP, Schreiner CA, Mehlman MA, Mackerer CR. 32P analysis of DNA adducts in tissues of benzene-treated rats. Environ Health Perspect 82:253-257 (1989).
10. Subrahmanyam VA, Ross DR, Eastmond DA, Smith MT. Potential role of free radicals in benzene-induced myelotoxicity and leukemia. Free Radic Biol Med 11:495-515 (1991).
11. Eastmond DA, Rupa DS, Hasegawa LS. Detection of hyper-diploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes. Mutat Res 322:9-20 (1994).
12. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780-2786 (1994).
13. Chen, H, Eastmond, DA. Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Carcinogenesis 16:2301-2307 (1995).
14. Ferguson LR, Baguley BC. Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24:245-261 (1994).
15. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T. Inhibition of intracelluar topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complexforming type inhibitors. Cancer Res 51:4909-4915 (1991).
16. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989:163-177 (1989).
17. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Can Chem Pharm 32:103-108 (1993).
18. Drake FH, Hofmann GA, Mong S-M, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49:2578-2583 (1989).
19. Assairi LM. DNA unknotting activity (DNA topoisomerase II) isolated from a thermophillic archaebacterium Sulfolbus is inhibited by novobiocin. Partial purification, identification of the two subunits and characteristics of the enzyme. Biochim Biophys Acta 1219:107-114 (1994).
20. Anderson RD, Berger NA. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 309:109-142 (1994).
21. Francis GE, Tejedor MC, Berney JJ, Chresta CM, Delgado C, Patel P. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells. Leukemia 8:121-128 (1994).
22. Gorbsky GJ. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)ptopane; ADR-529] and ICRF-159 (razoxane). Cancer Res 54:1042-1048 (1994).
23. Chen M, Beck WT. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase inhibitors merbarone and VM-26. Cancer Res 55:1509-1516 (1995).
24. Eastmond DA, Smith MT, Ruzo LO, Ross D. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase. Mol Pharmacol 30:674-679 (1986).
25. Sawahata T, Rickert DE, Greenlee WF. Metabolism of benzene and its metabolites in bone marrow. In: Toxicology of the Blood and Bone Marrow (Irons RD, ed). New York:Raven Press, 1985;141-148.
26. TopoGEN, Inc. Manual for Topoisomerase II Assay Kit. Columbus, OH, 1995.
27. Schattenberg DG, Stillman WS, Gruntmeir JJ, Helm KM, Irons RD, Ross D. Peroxidase activity in murine and human hematopoietic progenitor cells: potential relevance to benzene-induced toxicity. Mol Pharmacol 46:346-351 (1994).
28. Test ST, Weiss SJ. The generation and utilization of chlorinated oxidants by human neutrophils. Adv Free Radic Biol Med 2:91-116 (1986).
29. Kolachana P, Subrahmanyam W, Meyer KB, Zhang L, Smith MT. Benzene and its phenolic metabolites produce oxidative DNA damage in HL-60 cells in vitro and in the bone marrow in vivo. Cancer Res 53:1023-1026 (1993).
30. Rickert DE, Baker TS, Chism JP. Analytical approaches to the study of disposition of myelotoxic agents. Environ Health Perspect 39:5-10 (1981).
31. Negrini M, Felix CA, Martin C, Lange BJ, Nakamura T, Canaani E, Croce CM. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 53:4489-4492 (1993).
32. Ralph RK, Judd W, Pommier Y, Kohn KW. DNA Topoisomerases. In: Molecular Aspects of Anticancer Drugs-DNA Interactions. Vol 2 (Neidle S, Waring M, eds). New York:Macmillan, 1994;1-95.
33. Pedersen-Bjergaard J, Phillip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 55:119-124 (1991).
34. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Ped Oncol 23:86-98 (1994).
35. Van den Berghe H, Louwagie A, Orshove AB-V, David G, Verwilghen R. Chromosome analysis in two unusual malignant blood disorders presumably induced by benzene. Blood 53:558-566 (1979).
36. Fourth International Workshop on Chromosomes in Leukemia. Correlation of karyotype and occupational exposure to potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 11:326-331 (1984).
37. Li Y-S, Zhao Y-L, Jiang, Q-P, Yang C-L. Specific chromosome changes and non-occupational exposure to potentially carcinogenic agents in acute leukemia in China. Leuk Res 13:367-376 (1989).
38. Sole F, Caballin MR, Coll MD, Woessner S, Egozcue J. Acute lymphoblastic leukemia with t(4;11) in a patient previously exposed to a carcinogen. Cancer Genet Cytogenet 133-136 (1990).
39. Tasaka T, Nagai M, Sasaki K, Murata M, Taoka T, Ikeda K, Tanaka T, Abe T, Takahara J, Irino S. Translocation (3;21)(q26;q21) found in a patient with myelodysplastic syndrome and long-term exposure to organic solvents. Br J Haematol 82:473-474 (1992).
40. Smith M, Rothman N, Zhang L, Wang Y, Hayes R, Yin S. Molecular cytogenetics of humans exposed to benzene. Toxicologist 30:178 (1996).
41. Pollini G, Colombi R. II danno cromosomico midollare nell'anemia aplastica benzolica. La Medicina del Lavoro 55:241-255 (1964).
42. Erdogan G, Aksoy M. Cytogenetic studies in thirteen patients with pancytopenia and leukaemia associated with long-term exposure to benzene. New Istanb Contrib Clin Sci 10:230-247 (1973).
43. Antonucci R, Walker R, Herion J. Myelofibrosis and aplastic anemia: first report of the two disorders occuring sequentially in the same person. Am J Med 86:352-355 (1989).
44. Fishbein L. Genetic effects of benzene, toluene, and xylene. In: Environmental Carcinogens Methods of Analysis and Exposure Measurement. Vol 10: Benzene and Alkylated Benzenes (Fishbein L, O'Neill IK, eds). Lyon:International Agency for Research on Cancer, 1988;19-46.
45. Solary E, Bertrand R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymph 15:21-32 (1994).
46. Snyder R, Kalf GF. A perspective on benzene leukemogenesis. CRC Crit Rev Toxicol 24:177-209 (1994).
47. Oliveira NL, Kalf GF. Induced differentiation of HL-60 promyelocytic leukemia cells to monocyte/macrophages is inhibited by hydroquinone, a hematotoxic metabolite of benzene. Blood 79:627-633 (1992).
48. Major J, Jakab M, Kiss G, Tompa A. Chromosome aberration, sister-chromatid exchange, proliferative rate index, and serum thiocyanate concentration in smokers exposed to low-dose benzene. Environ Mol Mutagen 23:137-142 (1994).